{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T21:52:43Z","timestamp":1768773163623,"version":"3.49.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T00:00:00Z","timestamp":1518134400000},"content-version":"vor","delay-in-days":649,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.jchf.2016.02.012","type":"journal-article","created":{"date-parts":[[2016,4,26]],"date-time":"2016-04-26T14:58:41Z","timestamp":1461682721000},"page":"403-408","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Love of Angiotensin-Converting Enzyme Inhibitors in the Time of Cholera"],"prefix":"10.1016","volume":"4","author":[{"given":"Milton","family":"Packer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2016.02.012_bib1","doi-asserted-by":"crossref","unstructured":"Booker MK. The dangers of gullible reading: narrative as seduction in Garc\u00eda M\u00e1rquez\u2019 Love in the Time of Cholera. In: Studies in 20th Century Literature, volume 17, issue 2. Article 3. Available\u00a0at: http:\/\/dx.doi.org\/10.4148\/2334-4415.1321. Accessed February 4,\u00a02016.","DOI":"10.4148\/2334-4415.1321"},{"key":"10.1016\/j.jchf.2016.02.012_bib2","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","year":"1987","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2016.02.012_bib3","doi-asserted-by":"crossref","first-page":"478597","DOI":"10.1155\/2013\/478597","article-title":"Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-receptor blockers (ARBs) in patients at high risk of cardiovascular events: a meta-analysis of 10 randomised placebo-controlled trials","volume":"2013","author":"Ong","year":"2013","journal-title":"ISRN Cardiol"},{"key":"10.1016\/j.jchf.2016.02.012_bib4","doi-asserted-by":"crossref","first-page":"861","DOI":"10.7326\/0000605-200912150-00162","article-title":"Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart disease","volume":"151","author":"Baker","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jchf.2016.02.012_bib5","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/jamainternmed.2014.348","article-title":"Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis","volume":"174","author":"Cheng","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jchf.2016.02.012_bib6","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2016.02.012_bib7","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2016.02.012_bib8","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/S0735-1097(02)02304-5","article-title":"Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors","volume":"40","author":"Maggioni","year":"2002","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2016.02.012_bib9","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2016.02.012_bib10","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.ejheart.2004.02.002","article-title":"A\u00a0meta-analysis of the effect of angiotensin-converting enzyme inhibitors on functional capacity in patients with symptomatic left ventricular systolic dysfunction","volume":"6","author":"Abdulla","year":"2004","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2016.02.012_bib11","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1016\/j.ehj.2004.07.025","article-title":"Effect of candesartan on New York Heart Association functional class. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme","volume":"25","author":"O'Meara","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2016.02.012_bib12","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJM199108013250502","article-title":"A\u00a0comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure","volume":"325","author":"Cohn","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2016.02.012_bib13","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.cardfail.2004.11.004","article-title":"Effect of valsartan on quality of life when added to usual therapy for heart failure: results from the Valsartan Heart Failure Trial","volume":"11","author":"Majani","year":"2005","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jchf.2016.02.012_bib14","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1161\/CIRCHEARTFAILURE.109.912683","article-title":"Comparison of medical therapy dosing in outpatients cared for in cardiology practices with heart failure and reduced ejection fraction with and without device therapy: report from IMPROVE HF","volume":"3","author":"Heywood","year":"2010","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2016.02.012_bib15","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s00392-007-0617-6","article-title":"Guideline adherence for pharmacotherapy of chronic systolic heart failure in general practice: a closer look on evidence-based therapy","volume":"97","author":"Peters-Klimm","year":"2008","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.jchf.2016.02.012_bib16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1471-2296-6-19","article-title":"Perceived barriers for treatment of chronic heart failure in general practice: are they\u00a0affecting performance?","volume":"6","author":"Kasje","year":"2005","journal-title":"BMC Fam Pract"},{"key":"10.1016\/j.jchf.2016.02.012_bib17","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1053\/euhj.2000.2170","article-title":"European survey of primary care physician perceptions on heart failure diagnosis and management (Euro-HF)","volume":"21","author":"Hobbs","year":"2000","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2016.02.012_bib18","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1046\/j.1525-1497.1997.07110.x","article-title":"Utilization and dosing of angiotensin-converting enzyme inhibitors for heart failure. Effect of physician specialty and patient characteristics","volume":"12","author":"Chin","year":"1997","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1016\/j.jchf.2016.02.012_bib19","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.recesp.2015.03.008","article-title":"Adherence to the ESC heart failure treatment guidelines in Spain: ESC heart failure long-term registry","volume":"68","author":"Crespo-Leiro","year":"2015","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"10.1016\/j.jchf.2016.02.012_bib20","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2016.02.012_bib21","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/eurjhf\/hfs033","volume":"14","author":"McMurray","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2016.02.012_bib22","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1161\/01.CIR.100.23.2312","article-title":"Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group","volume":"100","author":"Packer","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2016.02.012_bib23","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/archinte.161.2.165","article-title":"Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival","volume":"161","author":"Massie","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jchf.2016.02.012_bib24","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/S0140-6736(09)61913-9","article-title":"Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial","volume":"374","author":"Konstam","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2016.02.012_bib25","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1001\/jama.2013.1954","article-title":"Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial","volume":"309","author":"Gheorghiade","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jchf.2016.02.012_bib26","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2016.02.012_bib27","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1093\/eurheartj\/ehv186","article-title":"Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients","volume":"36","author":"Desai","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2016.02.012_bib28","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.cardfail.2015.06.067","article-title":"Efficacy of LCZ696 persists at lower than target doses in the PARADIGM-HF Trial (abstr)","volume":"21","author":"Vardeny","year":"2015","journal-title":"J\u00a0Cardiac Failure"},{"key":"10.1016\/j.jchf.2016.02.012_bib29","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","article-title":"Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure","volume":"131","author":"Packer","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2016.02.012_bib30","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/00005344-199801000-00017","article-title":"Combined neutral endopeptidase and angiotensin-converting enzyme inhibition in heart failure: role of natriuretic peptides and angiotensin II","volume":"31","author":"Rademaker","year":"1998","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.jchf.2016.02.012_bib31","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","article-title":"Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial","volume":"17","author":"Kostis","year":"2004","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jchf.2016.02.012_bib32","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1001\/jama.289.6.712","article-title":"Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study","volume":"289","author":"Krum","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jchf.2016.02.012_bib33","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jacc.2005.04.038","article-title":"Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure","volume":"46","author":"Pitt","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2016.02.012_bib34","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.ahj.2006.02.028","article-title":"Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial","volume":"151","author":"McMurray","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.jchf.2016.02.012_bib35","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1161\/CIRCHEARTFAILURE.112.000173","article-title":"Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study","volume":"6","author":"Krum","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2016.02.012_bib36","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.cardfail.2004.02.008","article-title":"Consistency of the beneficial effect of metoprolol succinate extended release across a wide range dose of angiotensin-converting enzyme inhibitors and digitalis","volume":"10","author":"Ghali","year":"2004","journal-title":"J\u00a0Card Fail"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177916300452?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177916300452?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,13]],"date-time":"2018-09-13T00:54:20Z","timestamp":1536800060000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177916300452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S2213177916300452"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2016.02.012","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Love of Angiotensin-Converting Enzyme Inhibitors in the Time of Cholera","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2016.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 American College of Cardiology Foundation. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}